• CINNATROPIN 30iu Iran 1 pen x 10mg Somatropin HGH Injection

Cinnatropin 30 IU (10 mg) Somatropin Injection Pen

Recombinant Human Growth Hormone (rHGH) for Subcutaneous Injection

Product Overview & Composition

Cinnatropin Online Shop in Poland is a high-purity, pharmaceutical-grade recombinant human growth hormone (rHGH) solution formulated for subcutaneous administration. Manufactured by CinnaGen Co., a leading biotechnology company based in Iran, Cinnatropin contains synthetic Somatropin as its active pharmaceutical ingredient. Somatropin is produced using recombinant DNA technology, resulting in a polypeptide structure composed of 191 amino acids. This biological structure is identical in sequence, molecular weight, and physical properties to the naturally occurring human growth hormone secreted by the somatotroph cells of the anterior pituitary gland.

Each pre-filled pen delivery system contains 30 International Units (IU), equivalent to 10 mg of Somatropin, dissolved in a sterile liquid vehicle designed for stable shelf life and precise dosing. The pre-assembled injection device simplifies self-administration by eliminating manual reconstitutions or complex mixing procedures, ensuring that patient error is minimized and correct dosages are maintained throughout therapy.

Mechanism of Action

Somatropin exerts its biological effects by mimicking endogenous human growth hormone. Upon subcutaneous administration, Somatropin enters systemic circulation and binds to specific growth hormone receptors localized on target cell membranes across diverse anatomical tissues, including bone, skeletal muscle, adipose tissue, and the liver.

  1. Growth Stimulation & Linear Bone Growth: Increased circulating IGF-1 concentrations stimulate chondrocyte proliferation, osteoblast activity, and longitudinal bone growth before epiphyseal fusion occurs during late adolescence.
  2. Protein & Anabolic Metabolism: Somatropin accelerates intracellular amino acid transport and cellular protein synthesis, promoting nitrogen retention, muscular hypertrophy, and collagen matrix repair.
  3. Lipolysis & Fat Utilization: Somatropin enhances lipolysis by activating hormone-sensitive lipase in adipose cells, reducing overall body fat stores, mobilizing free fatty acids, and directing energy utilization away from glycogen breakdown.
  4. Carbohydrate & Electrolyte Regulation: Growth hormone influences glucose homeostasis by decreasing peripheral insulin sensitivity and hepatic glucose uptake, promoting steady glycogen stores while regulating sodium, potassium, and inorganic phosphate retention required for cellular tissue accretion.

Clinical Indications & Therapeutic Uses

Cinnatropin is indicated for conditions where normal endogenous growth hormone secretion is absent, insufficient, or impaired:

Pediatric Indications

  • Growth Hormone Deficiency (GHD): Treatment of children exhibiting severe growth failure due to inadequate endogenous pituitary growth hormone secretion.
  • Turner Syndrome: Long-term management of growth failure in female patients diagnosed with Turner syndrome (chromosomal monomy X).
  • Chronic Renal Insufficiency: Acceleration of linear growth in children experiencing growth retardation associated with chronic renal failure up to the point of renal transplantation.
  • Prader-Willi Syndrome (PWS) & Small for Gestational Age (SGA): Supporting linear height recovery in children born small for gestational age who fail to achieve catch-up growth by age two to four.

Adult Indications

  • Adult Growth Hormone Deficiency (AGHD): Replacement therapy in adults with established GHD resulting from pituitary micro- or macroadenomas, hypothalamic injury, surgical trauma, cranial radiation therapy, or childhood-onset pituitary deficiency persisting into adulthood. In adults, therapy aims to improve bone mineral density, optimize lipid profiles, increase lean muscle mass, and reduce visceral adiposity.

Dosage & Administration Guidelines

Cinnatropin must be administered under strict medical supervision and prescribed based on body weight, surface area, or individual biological response evaluated via serum IGF-1 monitoring.

  • Administration Method: Administered purely via subcutaneous injection into subcutaneous fat layers. Typical administration sites include the lower abdominal region (at least 2 inches away from the navel), outer thighs, or upper buttocks.
  • Rotation of Sites: Injection points must be systematically rotated with each daily dose to reduce the risk of localized lipoatrophy (loss of subcutaneous fat tissues) or localized tissue hardening.
  • Timing: Injections are usually administered once daily in the evening before bedtime. This dosing schedule closely mimics the naturally occurring circadian rhythm of nocturnal physiological growth hormone pulses.

Storage, Stability & Handling Requirements

Because Cinnatropin contains a complex biological polypeptide, maintaining strict cold chain logistics is crucial to preserving protein stability and preventing denaturation.

  • Refrigeration: The Cinnatropin pen must be stored continuously under refrigeration between 2°C and 8°C (36°F to 46°F).
  • Freezing Warning: Do not freeze. If the pen freezes or is exposed to sub-zero temperatures, the biological activity of Somatropin is destroyed, and the pen must be discarded immediately.
  • Light & Shock Protection: Store the injection pen inside its original outer package to protect the drug solution from direct sunlight and ultraviolet rays. Avoid vigorous shaking, as excessive physical agitation can cause aggregation and denaturation of the active protein molecules.

Precautions, Side Effects & Contraindications

Common Side Effects

Most adverse effects associated with Somatropin are related to fluid dynamics and tissue swelling during initial dosage titration:

  • Peripheral edema (mild swelling in fingers, ankles, or feet)
  • Arthralgia (joint stiffness and mild discomfort)
  • Myalgia (generalized muscle soreness)
  • Localized injection site reactions (transient erythema, itching, or pain)
  • Mild, transient headaches

Adverse Warnings & Regular Monitoring

  • Glucose Tolerance: Growth hormone exhibits anti-insulin activity. Patients with pre-existing diabetes mellitus or impaired glucose tolerance require frequent monitoring of blood glucose levels; anti-diabetic medication dosages may require adjustment.
  • Thyroid Function: Somatropin therapy can increase peripheral conversion of thyroid hormone T4 to T3, potentially unmasking central hypothyroidism. Thyroid panel testing should be performed periodically.
  • Fundoscopic Examination: Intracranial hypertension is a rare risk associated with Somatropin therapy. Any persistent, severe headache, visual disturbance, nausea, or vomiting requires medical evaluation.

Contraindications

Cinnatropin is strictly contraindicated in patients with:

  • Active malignancies or suspected intracranial neoplasm growth (all anti-tumor therapy must be completed prior to initiating treatment).
  • Acute critical illness resulting from complications following open-heart surgery, abdominal surgery, or multiple accidental traumas.
  • Severe respiratory impairment or acute respiratory failure.

Write a review

Note: HTML is not translated!
    Bad           Good

CINNATROPIN 30iu Iran 1 pen x 10mg Somatropin HGH Injection

  • Product Code: HGH
  • Availability: In Stock
  • $334.88


Available Options


Tags: CINNATROPIN 30iu Iran 1 pen x 10mg Somatropin HGH Injection